BrainsWay Ltd. (BWAY)
NASDAQ: BWAY · Real-Time Price · USD
14.84
-0.05 (-0.34%)
At close: Jul 16, 2026, 4:00 PM EDT
14.84
0.00 (0.00%)
After-hours: Jul 16, 2026, 4:10 PM EDT
BrainsWay Revenue
BrainsWay had revenue of $15.53M in the quarter ending March 31, 2026, with 34.63% growth. This brings the company's revenue in the last twelve months to $56.22M, up 29.37% year-over-year. In the year 2025, BrainsWay had annual revenue of $52.23M with 27.33% growth.
Revenue (ttm)
$56.22M
Revenue Growth
+29.37%
P/S Ratio
10.60
Revenue / Employee
$435,814
Employees
129
Market Cap
595.72M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 52.23M | 11.21M | 27.33% |
| Dec 31, 2024 | 41.02M | 9.23M | 29.04% |
| Dec 31, 2023 | 31.79M | 4.61M | 16.96% |
| Dec 31, 2022 | 27.18M | -2.48M | -8.36% |
| Dec 31, 2021 | 29.66M | 7.60M | 34.46% |
| Dec 31, 2020 | 22.06M | -1.04M | -4.52% |
| Dec 31, 2019 | 23.10M | 6.70M | 40.89% |
| Dec 31, 2018 | 16.40M | 5.25M | 47.12% |
| Dec 31, 2017 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orthofix Medical | 825.37M |
| Tactile Systems Technology | 343.52M |
| Viemed Healthcare | 286.57M |
| OrthoPediatrics | 243.30M |
| Cerus | 216.56M |
| Cytek Biosciences | 204.17M |
| Pacific Biosciences of California | 160.03M |
| Beta Bionics | 110.24M |
BWAY News
- 11 hours ago - BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral - GlobeNewsWire
- 17 days ago - BrainsWay (BWAY) Shares Positive Results from Real-World Study on PTSD and Depression - GuruFocus
- 17 days ago - Brainsway presents new Deep Transcranial Magnetic Stimulation data - TheFly
- 17 days ago - BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder - GlobeNewsWire
- 24 days ago - BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives - GlobeNewsWire
- 5 weeks ago - BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting - GlobeNewsWire
- 5 weeks ago - MEITAV INVESTMENT HOUSE LTD Acquires Significant Stake in BrainsWay Ltd - GuruFocus
- 7 weeks ago - Brainsway price target raised to $17 from $15 at H.C. Wainwright - TheFly